Etoposide-based therapy for severe forms of COVID-19
Fecha
2020Autor
Hamizi, Kamel
Aouidane, Souhila
Belaaloui, Ghania
Documentos PDF
Imagenes y Videos
Resumen
The new coronavirus infection COVID-19 has quickly become a global health emergency. Mortality is principally
due to severe Acute Respiratory Distress Syndrome (ARDS) which relays only on supportive treatment.
Numerous pathological, clinical and laboratory findings rise the similarity between moderate to severe COVID19 and haemophagocytic lymphohistiocytosis (HLH). Etoposide-based protocol including dexametasone is the
standard of care for secondary HLH. The protocol has been successfully used in HLHs that are secondary to EBV
and H1N1 infections by inducing complete response and prolonged survival. These observations prompt to
consider this cytotoxic therapy in HLH associated to moderately severe to severe forms of COVID-19.
Palabras clave
COVID-19; Haemophagocytic lymphohistiocytosis; HLH; EtoposideEnlace al recurso
https://doi.org/10.1016/j.mehy.2020.109826Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.